Loading stock data…
Pulse Biosciences, Inc (PLSE)
$29.24+0.79 (+2.78%)
Market ClosedLast close Jun 29
Pulse Biosciences, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Pulse Biosciences, Inc. in the Healthcare sector is trading at $29.24 with a market capitalization of $1.7B. Wall Street consensus targets $30.67 (3 analysts), implying a +4.9% move over the next 12 months. The stock is currently near its 52-week high of $31.00, remaining 54.1% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $401,000↑ | $264,000↑ | $86,000 | $0 | $0 |
| Gross Profit | $31,000↑ | $4,000↑ | -$193,000 | — | $0 |
| Operating Income | -$19.15M↓ | -$18.25M↑ | -$20.37M↓ | -$20.27M↓ | -$18.04M |
| Net Income | -$18.58M↓ | -$17.43M↑ | -$19.39M↓ | -$19.17M↓ | -$16.80M |
Peer Comparison
JNJUNHPFE
Fundamentals
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.73B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.63
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-112.47%
Volume
Today's trading volume
462,349
Recent News
Did New Analyst Coverage and Insider Buying Just Shift Pulse Biosciences' (PLSE) Investment Narrative?
Recently, Canaccord Genuity and CCORF initiated coverage on Pulse Biosciences, highlighting its nanosecond pulsed field ablation platform for cardiac applications and pointing to recent insider share purchases by top executives. The combination of external analyst attention and meaningful insider buying has drawn fresh focus to Pulse Biosciences’ differentiated technology in the competitive cardiac ablation field. Next, we’ll examine how this new bullish analyst coverage around Pulse’s...
Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy
Does Pulse Biosciences, Inc (PLSE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors.
Pulse Biosciences, a developer of non-thermal bioelectric treatments, reported a notable insider buy amid recent stock price gains.
Is Pulse Biosciences (PLSE) Quietly Redefining Its Core Identity Around Atrial Fibrillation?
In early May 2026, Pulse Biosciences reported a wider first-quarter net loss of US$18.58 million and basic loss per share of US$0.27, while highlighting strong European feasibility data for its nPulse cardiac catheter in atrial fibrillation and the start of enrollment in its pivotal U.S. NANOPULSE-AF trial. The company is also reallocating more clinical and R&D resources toward its nPulse cardiac catheter program, signaling a meaningful internal shift toward atrial fibrillation as its lead...
Pulse Biosciences Q1 Earnings Call Highlights
Pulse Biosciences (NASDAQ:PLSE) said it is sharpening its focus on its nanosecond pulsed field ablation platform for atrial fibrillation after reporting first-quarter 2026 results and highlighting new clinical data from its cardiac catheter program. On the company’s earnings call, Co-Chairman and C